Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Type:
Grant
Filed:
June 25, 2009
Date of Patent:
January 8, 2013
Assignee:
ESBATech, an Alcon Biomedical Research Unit, LLC
Inventors:
Leonardo Borras, David Urech, Tea Gunde
Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
Type:
Grant
Filed:
June 25, 2009
Date of Patent:
October 23, 2012
Assignee:
ESBATech, an Alcon Biomedical Research Unit, LLC
Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
October 2, 2012
Assignee:
ESBATech, an Alcon Biomedical Research Unit, LLC.
Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.
Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
Type:
Grant
Filed:
August 17, 2011
Date of Patent:
August 28, 2012
Assignees:
Alcon Research, Ltd., Astellas Pharma Inc.
Inventors:
Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
July 24, 2012
Assignee:
ESBATech, an Alcon Biomedical Research Unit, LLC
Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
Type:
Grant
Filed:
June 30, 2011
Date of Patent:
July 17, 2012
Assignee:
Alcon Research, Ltd.
Inventors:
John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
Abstract: Methods of treating symptoms of dry eye by administering a fatty acid amide or inhibitors of fatty acid amide hydrolase (FAAH) are disclosed. Methods of preventing or alleviating ocular pain by administering a fatty acid amide or FAAH inhibitors are also disclosed.
Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
Type:
Grant
Filed:
April 12, 2011
Date of Patent:
May 8, 2012
Assignee:
Novartis AG
Inventors:
Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.
Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Type:
Grant
Filed:
June 6, 2006
Date of Patent:
November 29, 2011
Assignee:
ESBATech, an Alcon Biomedical Research Unit, LLC
Inventors:
Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
Type:
Grant
Filed:
April 13, 2007
Date of Patent:
November 1, 2011
Assignee:
Alcon Research, Ltd.
Inventors:
John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
Type:
Grant
Filed:
April 10, 2007
Date of Patent:
September 13, 2011
Assignee:
Alcon Research, Ltd.
Inventors:
John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.